Original Research
Accepted on 30 Sep 2025
Evaluating the Effectiveness of Integrated Care in Targeted Therapy for Patients with Chronic Lymphocytic Leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1685510
Type at least 3 characters
1,936 articles
Original Research
Accepted on 30 Sep 2025
The Prognostic Significance of Incomplete Hematological Recovery in Pediatric Patients with Low/Intermediate Risk AML and Negative MRD after Induction 1
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1661036
Original Research
Published on 30 Sep 2025
The significance of PET/CT combined with machine learning models for the classification of lymphoma involvement and metastases in enlarged lymph nodes
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1643924
- 145 views
Systematic Review
Accepted on 29 Sep 2025
Comparing therapeutic effects of hematopoietic stem cell transplantation, tyrosine kinase inhibitors and chemotherapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1627825
Original Research
Accepted on 29 Sep 2025
B7-H7 knockdown suppresses the proliferation, metastasis, and drug resistance of B-cell non-Hodgkin lymphoma cells by inhibiting the PI3K/Akt pathway
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1665309
Case Report
Accepted on 29 Sep 2025
Immunophenotypically diverse immature patterns, including variable TdT expression, in aggressive B-cell lymphomas and leukemia with MYC rearrangement
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1684005
Case Report
Published on 25 Sep 2025
Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1671124
- 2,124 views
Mini Review
Accepted on 24 Sep 2025
Anti-angiogenesis in human lymphomas. New insights
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1636332
- 486 views
Correction
Accepted on 24 Sep 2025
Correction: TARGETING RAB7 IN HUMAN B LYMPHOMA BY A SMALL MOLECULE INHIBITOR ARRESTS TUMOR CELL GROWTH
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1711784
- 466 views
Perspective
Accepted on 24 Sep 2025
Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1642472
- 493 views
Original Research
Accepted on 23 Sep 2025
Laboratory and Imaging Risk Factors for Mortality in Children with Primary Hemophagocytic Lymphohistiocytosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1668762
- 246 views
Case Report
Published on 23 Sep 2025
Efficacy of brentuximab vedotin combined with sintilimab in relapsed/refractory DLBCL patient with secondary hemophagocytic syndrome: a case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1531713
- 624 views
Mini Review
Published on 23 Sep 2025
Immunoparesis in multiple myeloma: a current overview
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1628144
- 401 views
Review
Accepted on 22 Sep 2025
Research Advances in the Adjunctive Diagnosis of Acute Myeloid Leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1634935
- 378 views
Case Report
Published on 22 Sep 2025
Erdheim-Chester disease: unveiling hidden manifestations through two case reports
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1611907
- 394 views
Original Research
Published on 22 Sep 2025
Targeting RAB7 in human B lymphoma by a small molecule inhibitor arrests tumor cell growth
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1616519
- 811 views